

RECEIVED  
CENTRAL FAX CENTER

OCT 13 2005

901 New York Avenue, NW ■ Washington, DC 20001-4413 ■ 202.408.4000 ■ Fax 202.408.4400  
www.finnegan.com



## FACSIMILE TRANSMITTAL

### TO

Name: Examiner T. Truong  
Company: USPTO  
Fax Number: 571.273.8300  
Phone Number: 571.272.0676  
Date: October 13, 2005  
Subject: U.S.S.N. 10/674,350

### FROM

Name: Denise Main  
Phone Number: 202.408.4228  
Fax Number Verified by: J. Lamb  
Total Pages (including cover):  
Our File No.: 02481.1655-01

Confirmation Copy to Follow: No

### MESSAGE

## CERTIFICATE OF TRANSMISSION UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on October 13, 2005.

By: \_\_\_\_\_

Anthony C. Tridico

RECEIVED  
OIPE/IAP

OCT 14 2005

If there is a problem with this transmission, notify the sender at the number above.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

RECEIVED  
CENTRAL FAX CENTER

OCT 13 2005

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1655-01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Ursula SCHINDLER et al. ) Group Art Unit: 1624  
)  
Application No.: 10/674,350 ) Examiner: T. Truong  
)  
Filed: October 1, 2003 )  
)  
For: SUBSTITUTED 4-AMINO-2-ARYL- )  
TETRAHYDROQUINAZOLINES, )  
THEIR PREPARATION, THEIR USE )  
AND PHARMACEUTICAL )  
PREPARATIONS COMPRISING )  
THEM )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**TERMINAL DISCLAIMER**

Assignee, Aventis Pharma Deutschland GmbH, duly organized under the laws of Germany, and having its principal place of business at Patent-und Lizenzabteilung, Geb. K 801, D-65926 Frankfurt am Main, Germany, represents that it is the assignee of the entire right, title and interest in and to the above-identified application, Application No. 10/674,350, filed October 1, 2003 for SUBSTITUTED 4-AMINO-2-ARYL-TETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM in the names of Dr. Ursula Schindler, Dr. Karl Schönafinger, and Dr. Hartmut STROBEL, as indicated by assignment duly recorded in the United States Patent and Trademark Office at Reel

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1655-01

10715, Frame 0140 on April 18, 2000. Assignee, Aventis Pharma Deutschland GmbH, further represents that it is the assignee of the entire right, title and interest in and to U.S. Patent No. 6,660,746, as indicated by assignment duly recorded in the United States Patent and Trademark Office at Reel 10715, Frame 0140 on April 18, 2000.

To obviate a double patenting rejection, assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior patent No. 6,660,746, and hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1655-01

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), please charge the required fee of \$130.00 to our Deposit Account No. 06-0916.

If there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 06-0916


The undersigned is an attorney of record.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: October 13, 2005

By:

  
Anthony C. Tridico  
Reg. No. 45,958